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Abstract
Background: Signet ring cells (SRCs) often accompany gastrointestinal carcinoma, referred to as SRC carcinoma;
however, breast cancers containing SRCs have not been well characterized, leaving the prognostic significance of
SRCs undetermined. We have described clinicopathological characteristics of patients with breast cancer containing
SRCs in relation to the expression levels of MUC1, MUC2, MUC4, MUC5AC, and MUC6.
Methods: Twenty-two breast cancer cases with variable degrees of SRC population were retrospectively studied.
Each case was categorized as high (>31 %) or low (<30 %) SRC tumor. The SRCs were morphologically classified
into the intra-cytoplasmic lumen (ICL) type, or the non-ICL type. The expression levels of MUC1, MUC2, MUC4,
MUC5AC and MUC6 were determined immunohistochemically. Depending on its subcellular localization, MUC1
was categorized as the luminal and cytoplasmic (LC) type, or the cytoplasmic with circumferential membranous
accentuation (CM) type. These histological findings were compared with other clinicopathological parameters.
Results: The series consisted of invasive ductal carcinoma (n = 9), invasive lobular carcinoma (n = 9), and mucinous
carcinoma (n = 4) cases. The SRC population accounted for 8–81 % of the tumor cells. Eight cases had ICL type
SRCs, and the remaining 14 had non-ICL type SRCs. Neither the high (n = 12) and low (n = 10) percentage of SRCs,
nor the SRC types affected the clinicopathological parameters. In the low MUC1 group (n = 11), larger tumors,
higher nuclear grade, lymph node metastasis, and negativity for estrogen receptor was more frequently identified
compared to the high MUC1 group (n = 11; p = 0.01, p = 0.002, p = 0.008, and p = 0.02, respectively). The CM group
(n = 7) had more patients with large-sized tumors, lymph node metastasis, lymphovascular invasion, and higher Ki67
indices than the LC group (n = 15; p = 0.04, p = 0.001, p = 0.006, and p = 0.03, respectively). The expression levels of
MUC2, MUC4, MUC5AC, and MUC6 showed no clinicopathological significance. Two patients with low MUC1
expression and CM patterns had tumor recurrence, resulting in death, while all the other patients survived without
recurrence.
Conclusion: Our results demonstrate that in breast cancers containing SRCs, low MUC1 expression and/or its CM
subcellular localization patterns are associated with unfavorable clinicopathological factors. The utility of MUC1
expression as a prognostic marker remains to be verified in future studies.
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Background
Signet ring cells (SRCs) are types of epithelial cells mor-
phologically characterized by intracytoplasmic mucins
displacing the nucleus to one side of the cell. SRCs are
often involved in the gastrointestinal carcinoma, re-
ferred to as the SRC carcinoma when SRCs constitute a
major component of the tumor [1–4]. Saphir first de-
scribed the presence of SRCs in the breast cancer [5].
However, breast carcinomas predominantly composed
of SRCs are rarely encountered in daily clinical practice
[6–8]. SRCs of the breast tumors were initially thought
to originate from invasive lobular carcinoma (ILC),
whereas later studies found that the SRCs can derive
from other types of carcinoma besides ILC, including
invasive ductal carcinoma of no special type (IDC) and
mucinous carcinoma (MC) [9–13]. Likewise, the diag-
nostic criteria for SRC carcinoma of the breast have not
been strictly defined yet, and thus SRC carcinoma has
not been listed as a distinct disease entity in the current
WHO classification of breast tumors [14]. Therefore, it
is imperative to conduct studies that extensively reveal
the characteristics and clinical significance of SRCs in
breast carcinomas.
Mucins are high molecular weight heavily O-glycosylated
glycoproteins produced by various epithelial cells and
malignant tumors, labelled with a number reflecting
the order in which each mucin was initially discovered
[15]. Membrane-bound forms of mucin include MUC1,
MUC3A, MUC3B, MUC4, MUC12, MUC13 and MUC17,
and the secreted forms include MUC2, MUC5AC,
MUC5B and MUC6. The aberrant expression of mucins
could be associated with cancer growth, differentiation,
transformation, and invasion [16]. In breast cancer, most
tumors express MUC1 and MUC3, and the expression of
MUC2, MUC4, MUC5AC, and MUC6 is variable or lim-
ited [17]. A previous study reported an inverse association
between the degree of MUC1 expression, and tumor grade
and a recurrence rate [17]. In addition, increased cytoplas-
mic staining of MUC1 with circumferential membranous
accentuation could be related to the aggressive behavior of
tumors as MUC1 is normally localized to apical sites of
breast ductal epithelium [17–19]. These findings indicate
that MUC1 can be a potential prognostic indicator of pa-
tients with breast cancer. However, reports on the mucin
expression profiles of breast cancer containing SRCs are
still limited [20–22]. In particular, the clinical significance
of the mucin expression profiles of SRCs in breast carcin-
oma remains to be further investigated.
In the present study, we investigated the clinicopatho-
logical features of 22 patients with breast carcinoma con-
taining SRCs to variable degrees. We divided the patients
into high and low SRC groups, comprising more or less
than 30 % of the tumor cells, respectively, to assess the
effect of SRC population on other clinicopathological
features. We also morphologically categorized SRCs
into the intra-cytoplasmic lumen (ICL) and non-ICL
types, according to the 2013 WHO classification, to see
if SRC types may have clinical significance [14]. We fur-
ther performed immunohistochemical analysis to assess
the expression of MUC1, MUC2, MUC4, MUC5AC,
and MUC6 to delineate the prognostic significance of
the expression level of each mucin with a particular




We searched the archives of the Department of Diagnostic
Pathology, Nippon Medical School Hospital (Tokyo,
Japan) between January 2006 and August 2015. We
identified 22 cases with “SRC” in the diagnostic lines
and/or histological description. Patients with tumors in
the breast metastasized from primary carcinomas in
other organs (the gastrointestinal system or the lung)
were excluded. We reviewed all the hematoxylin and
eosin-stained histological specimens for each case to
confirm the presence of SRCs within the tumor. The
cytomorphology of SRCs was categorized as the ICL
and non-ICL types as described elsewhere [14]. Briefly,
the ICL type is characterized by the presence of ICL
with targetoid appearance, whereas the non-ICL type
has abundant intracytoplasmic mucin as observed in
gastric carcinoma. Nuclear atypia was graded by com-
bining four nuclear features including 1) enlargement,
2) distinct nucleolus, 3) hyperchromasia and 4) pleo-
morphism, and was expressed as grade 1: none or 1 of
the features, grade 2: 2 or 3 of the features, and grade
3: all of the features [23]. The population of SRCs in
each case was assessed quantitatively by two patholo-
gists (RO and TS) who independently determined the
percentage of SRCs among the total number of tumor
cells evaluated in at least 20 high power fields focusing
on the SRC-rich areas. The cases were further stratified
into SRC-high (>31 %) and SRC-low (<30 %) groups.
Clinical data extracted from medical charts and path-
ology reports were reviewed. This study was conducted
in accordance with the principles embodied in the
Declaration of Helsinki (revised in Brazil 2013). Patients’
consents were obtained for the use of clinical samples
for research purposes according to the regulations
defined by the Ethics Committee of Nippon Medical
School Hospital.
Immunohistochemical stainings
Immunohistochemical staining was performed on
formalin-fixed histological sections of the tumors with
primary antibodies by using the standard avidin-biotin-
peroxidase complex technique. The following antibodies
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were used: monoclonal mouse anti-human MUC-1 (NCL-
MUC-1, dilution 1:100; Leica Biosystems Newcastle Ltd,
UK), monoclonal mouse anti-human MUC-2 (NCL-
MUC-2, dilution 1:100; Leica Biosystems Newcastle Ltd),
monoclonal mouse anti-human MUC-4 (1G8, dilution
1:100; Santa Cruz Biotechnology, USA), monoclonal
mouse anti-human MUC-5 AC (NCL-MUC-5 AC, dilu-
tion 1:100; Leica Biosystems Newcastle Ltd), monoclonal
mouse anti-human MUC-6 (NCL-MUC-6, dilution 1:100;
Leica Biosystems Newcastle Ltd), E-cadherin (NCH-38,
dilution 1:50; DAKO, Denmark), monoclonal rabbit anti-
human estrogen receptor (ER) (SP1, dilution 1:1; Ventana
Medical Systems, USA), monoclonal rabbit anti-human
progesterone receptor (PgR) (1E2, dilution 1:1; Ventana
Medical Systems), monoclonal rabbit anti-human HER2/
neu (4B5, dilution 1:1; Ventana Medical Systems), and
monoclonal mouse anti-human Ki67 (M7240, dilution
1:100; DAKO, Denmark). Positive and negative controls
for each antibody were used.
MUC1 positivity was determined using the modified
H-score [17, 24]. The score consists of the sum of the
percent of tumor cell staining multiplied by an ordinal
value corresponding to the intensity level (0 = none, 1 =
weak, 2 =moderate, and 3 = strong). With 4 intensity
levels, the resulting score range was from 0 (no staining
in any of the tumor cells) to 300 (diffuse intense staining
in all the tumor cells). The cases were then stratified
into two groups below and above the median score as
low and high groups, respectively. As previous reports
indicated that the altered subcellular localizations of
MUC1 is of prognostic significance, the MUC1 localization
pattern was further categorized as luminal and/or cytoplas-
mic without membranous accentuation (LC) pattern or as
cytoplasmic with circumferential membranous accentu-
ation (CM) pattern [17–19, 25]. In the assessment of
MUC2, MUC5AC, and MUC6 expression, positivity was
defined by the detection of positive expression in > 10 % of
the tumor cells.
The positivity of ER and PgR expression was graded
according to the guidelines established at the St Gallen
Consensus Conference [26]. Briefly, ER and PgR status
should be judged as positive if any positive cells are de-
tected within the tumor. The HER2 status was assessed
according to the guidelines defined by American Society
of Clinical Oncology / College of American Pathologists
[27]. All immunohistochemical stains were blindly
assessed by two pathologists (RO and TS), independently.
Statistical analysis
All data are shown as mean values ± standard error of
the mean (SEM). The chi-square and Fisher’s exact
tests were used to analyze associations among clinico-
pathological variables. Multivariate analysis of prognos-
tic parameters was performed using logistic regression.
Statistical analyses were performed using JMP statistical
software, version 11 (SAS Institute Inc., Cary, NC,
USA). A p-value of < 0.05 was considered statistically
significant.
Results
Clinicopathological profiles of breast carcinoma in
association with SRCs
The clinicopathological features of patients are summa-
rized in Table 1. Representative histopathological find-
ings are shown in Fig. 1. The histological variants of
the tumors consisted of IDC (n = 9), ILC (n = 9), and
MC (n = 4). ILC diagnosis was confirmed by identifying
the loss of E-cadherin expression. Patients’ age ranged
from 42 to 85 (mean 64 ± 12) years. The tumor size
ranged from 0.7 to 6.8 (mean 2.4 ± 1.4) cm. Four cases
of IDC, 3 of ILC, and 1 of MC involved grade 2 or 3
nuclear atypia, whereas 5 cases of IDC, 6 of ILC, and 3
of MC had grade 1 nuclear atypia. The SRC population
constituted 8 to 81 % (mean 42.2 ± 23) of tumor cells in
each case. Tumors of 8 cases had ICL type SRCs,
whereas the remaining 14 cases had non-ICL type
SRCs. Axillary lymph nodes were positive for metastatic
carcinoma in 5 patients with IDC, 3 patients with ILC,
and none of the patients with MC. Lymphovascular in-
vasion was observed in 4 patients with IDC, 3 patients
with ILC patients, and in none of the patients with MC.
None of the patients had distant metastatic carcinoma
in other organs at the time of first presentation. With
regards to the hormonal status of the tumor cells, 2
cases of IDC, 3 of ILC and 1 of MC showed a triple
negative phenotype, 1 patient with IDC showed HER2
type, and all the others showed type A (Table 2). Dur-
ing the clinical follow-up period that ranged from 12 to
137 (mean 49 ± 38) months, two patients (case 3 and
case 12) developed breast tumor recurrence in the liver
and brain, respectively, and they both eventually passed
away. All the other patients survived with no recur-
rence of the tumor within the follow-up period.
The association between the SRC population and types
and the clinicopathological features are summarized in
Table 3. In a total of 12 patients, 5 with IDC, 4 with ILC,
and 3 with MC had SRC-high (>31 %) populations
whereas 10 patients, 4 with IDC, 5 with ILC, and 1 with
MC had SRC-low (<30 %) populations. There was no sig-
nificant association between the SRC population groups
and any of the clinicopathological parameters examined.
The non-ICL type of SRC was observed in 7 cases of IDC
and all the cases of MC (Fig. 1b, d). By contrast, the ICL
type was observed in 6 cases of ILC and 2 cases of IDC
(Table 3, p < 0.035) (Fig. 1a, c). These findings are consist-
ent with a previous report, which demonstrates that the
ICL type SRCs are more commonly identified in ILC than
in IDC [28]. There was no significant association between
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the SRC types and any of the clinicopathological parame-
ters investigated (Table 3).
MUC1 subcellular localization patterns and expression
levels in association with clinicopathological variables
MUC1 subcellular localization patterns (LC or CM) and
expression levels (high or low), and their association with
the clinicopathological variables are shown in Tables 2
and 4, respectively. Representative immunohistochemical
findings of MUC1 for each localization pattern are pre-
sented in Fig. 2. The LC pattern was observed in 15 cases,
while the CM pattern was observed in 7 cases. Six patients
in the CM group had large tumor sizes, whereas 9 from
the LC group had small sizes (p = 0.04). Metastatic car-
cinoma was identified in axillary lymph nodes of 6 pa-
tients from the CM group, and 2 patients from the LC
group (p = 0.001). Five patients of CM group had lym-
phovascular invasion of the tumor, which was absent
in the majority (n = 13) of the patients in the LC group
(p = 0.006). High Ki67 indices (>20 %) were noted in 4
patients in the CM group; however, most (n = 13) of
the LC group had low Ki67 indices (<19 %) (p = 0.03).
Two patients in the CM group had tumor recurrences,
whereas none of the patients in the LC group did (p =
0.03). However, multivariate analysis revealed that MUC
localization pattern was not independently responsible for
an increase in recurrence rate (p = 0.98). There was no sig-
nificant correlation between the subcellular MUC1 ex-
pression patterns and the other variables including age,
histological types, SRC population, SRC types, nuclear
grade, and hormonal status.
High expression of MUC1 was detected in 11 cases,
while the remaining 11 cases had low MUC1 expression.
Nine patients in the group with low MUC1 expression
had larger tumors, whereas 8 patients in the high MUC1
expression group had small-sized tumors (p = 0.01).
Eight patients in the low MUC1 group had nuclear
grades of either 2 or 3; however, all the patients in the
high MUC1 expression group had a nuclear grade of 1
(p = 0.002). Seven patients in the group with low MUC1
expression had metastatic carcinoma in the axillary
lymph nodes, whereas only 1 patient had a positive
lymph node in the high MUC1 group (p = 0.008). Lym-
phovascular invasion was identified in 5 patients of the
Table 1 Clinicopathological variables of patients with breast cancer containing signet ring cells
Case Age Tumor site Histological type Tumor size
(cm)
Nuclear grade SRC population
(%)
SRC type LN status LVI Recurrence Follow-up
(months)
Status
1 57 R-UOQ IDC 2.1 3 18 Non-ICL + + − 137 Alive
2 42 L-UOQ IDC 3 1 30 Non-ICL + + − 108 Alive
3 45 L-LIQ IDC 5 3 80 Non-ICL + + + liver 66 Dead
4 72 R-UOQ IDC 2.8 2 21 Non-ICL − − − 67 Alive
5 74 R-UOQ IDC 2.2 1 39 ICL − − − 30 Alive
6 64 R-UOQ IDC 2.7 1 30 Non-ICL + + − 12 Alive
7 65 R-UOQ IDC 0.7 1 55 ICL + − − 45 Alive
8 48 R-LIQ IDC 2.1 2 79 Non-ICL − − − 12 Alive
9 78 L-LOQ IDC 1.2 1 81 Non-ICL − − − 12 Alive
10 85 L-IQT ILC 3.5 1 35 ICL − − − 50 Alive
11 62 R-OQT ILC 6.8 2 73 ICL − − − 64 Alive
12 80 R-UOQ ILC 3.1 2 22 ICL + + + brain 31 Dead
13 57 R-UOQ ILC 1.8 1 8 Non-ICL − − − 74 Alive
14 47 L-UOQ ILC 2.8 1 62 Non-ICL + + − 72 Alive
15 55 R-OQT ILC 2 1 19 ICL − + − 20 Alive
16 76 R-UOQ ILC 1.2 3 20 Non-ICL + − − 14 Alive
17 52 R-LOQ ILC 1 1 28 ICL − − − 12 Alive
18 76 L-UQT ILC 1.8 1 47 ICL − − − 12 Alive
19 78 R-OQT MC 1.5 1 14 Non-ICL − − − 125 Alive
20 63 R-LOQ MC 0.7 1 65 Non-ICL − − − 79 Alive
21 66 L-UOQ MC 1.5 1 62 Non-ICL − − − 35 Alive
22 68 R-OQT MC 2.5 2 42 Non-ICL − − − 16 Alive
Abbreviations: SRC signet ring cell, LN lymph node, LVI lymphovascular invasion, R right, L left, UOQ upper outer quadrant, LOQ lower outer quadrant, LIQ lower
inner quadrant, IQT inner quadrant transition, OQT outer quadrant transition, UQT upper quadrant transition, IDC invasive ductal carcinoma, ILC invasive lobular
carcinoma, MC mucinous carcinoma, ICL intracytoplasmic lumen
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Fig. 1 Signet ring cells (SRCs) in invasive ductal carcinoma of no special type (a and b), invasive lobular carcinoma (c), and mucinous carcinoma
(d). The intracytoplasmic lumen (ICL) type of SRCs is represented by discrete vacuoles with targetoid appearance (a and c), whereas the non-ICL
type has abundant intracytoplasmic mucin dislodging the nucleus to one end of the cells, as seen in gastric carcinoma (b and d). Hematoxylin
and eosin staining (a–d). Original magnification × 600 (a–d)
Table 2 Immunohistochemical profile of breast cancers containing signet ring cells
Case MUC1 MUC2 MUC4 MUC5 MUC6 ER PgR HER2 Ki67
Subcellular localization Level
1 CM Low − − − − + + − 30
2 LC Low − − − + + + − 10
3 CM Low − + + + − − − 20
4 LC Low − − + − − − + 10
5 LC High − − − − + − − 5
6 CM Low − − − − + − − 30
7 CM Low − − − − + + − 30
8 LC Low − + − − − − − 5
9 LC High − − − + + + − 10
10 LC High − − − + + + − 10
11 CM Low − − − − − − − 10
12 CM Low − − − + − − − 10
13 LC High − − − + + + − 10
14 CM High − − − − + + − 10
15 LC High − − − + + + − 20
16 LC Low − − − − − − − 20
17 LC High − − − + + + − 5
18 LC High − − − − + + − 5
19 LC High − − − − + + − 10
20 LC High + − − + − − − 10
21 LC High − − − − + + − 5
22 LC Low + − − + + − − 5
Abbreviations: CM cytoplasmic with circumferential accentuation pattern, LC luminal and cytoplasmic pattern
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group with low MUC1 expression, while it was observed
only in 2 patients of the high MUC1 expression group;
however, the difference was not statistically significant
(p = 0.17). In the group with low MUC1 expression, 6
cases were negative for ER, while 10 cases were positive
for ER in the group with high MUC1 expression (p =
0.02). Triple negative type cancer was observed in 5
cases of the group with low MUC1 expression, whereas
Table 3 Association of SRC population and types with
clinicopathological profile










> 65 4 7 0.39 5 6 0.37
< 64 6 5 3 8
Histological type
IDC 4 5 0.59 2 7 0.035
ILC 5 4 6 3
MC 1 3 0 4
Tumor size (cm)
> 2.1 5 7 0.69 4 8 0.75
< 2.0 5 5 4 6
Nuclear grade
1 6 8 0.94 6 8 0.7
2 2 2 1 3
3 2 2 1 3
LN status
Positive 5 3 0.22 2 6 0.4
Negative 5 9 6 8
LVI
Positive 5 2 0.09 2 5 0.6
Negative 5 10 6 9
ER
Positive 7 8 0.87 6 9 0.6
Negative 3 4 2 5
TN vs other types
TN 2 4 0.48 2 4 0.86
Other types 8 8 6 10
Ki67 (%)
> 20 4 2 0.22 2 4 0.86
< 19 6 10 6 10
Recurrence
Positive 1 1 0.89 1 1 0.67
Negative 9 11 7 13
Abbreviations: SRC signet ring cell, ICL intracytoplasmic lumen, IDC invasive
ductal carcinoma, ILC invasive lobular carcinoma, MC mucinous carcinoma, LN
lymph node, LVI lymphovascular invasion, TN triple negative
Table 4 Association of MUC1 expression levels and subcellular
localization patterns with clinicopathological profile










> 61 7 4 0.65 5 6 0.66
< 60 8 3 6 5
Histological type
IDC 5 4 0.28 7 2 0.09
ILC 6 3 3 6
MC 4 0 1 3
SRC (%)
> 31 8 4 0.87 5 7 0.39
< 30 7 3 6 4
SRC type
Non-ICL 10 4 0.67 8 6 0.38
ICL 5 3 3 5
Tumor size (cm)
> 2.1 6 6 0.04 9 3 0.01
< 2.0 9 1 2 8
Nuclear grade
1 11 3 0.28 3 11 0.002
2 3 2 5 0
3 1 2 3 0
LN status
Positive 2 6 0.001 7 1 0.008
Negative 13 1 4 10
LVI
Positive 2 5 0.006 5 2 0.17
Negative 13 2 6 9
ER
Positive 11 4 0.45 5 10 0.02
Negative 4 3 6 1
TN vs other types
TN 3 3 0.26 5 1 0.055
Other types 12 4 6 10
Ki67 (%)
> 20 2 4 0.03 5 1 0.055
< 19 13 3 6 10
Recurrence
Positive 0 2 0.03 2 0 0.14
Negative 15 5 9 11
Abbreviations: LC luminal and cytoplasmic pattern, CM cytoplasmic with
circumferential accentuation pattern, SRC signet ring cell, ICL intracytoplasmic
lumen, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, MC
mucinous carcinoma, LN lymph node, LVI lymphovascular invasion, TN
triple negative
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only 1 case in the group with high MUC1 expression ex-
hibited this phenotype with borderline significance (p =
0.055). Five patients in the low MUC1 expression group
had high Ki67 indices; however, most of the patients (n
= 10) in the high MUC1 group had low Ki67 indices
with borderline significance (p = 0.055). Two patients
from the low MUC1 expression group had recurrences
of the tumor within the follow-up period, whereas none
of the patients in the group with high MUC1 expression
did, although the difference was not statistically signifi-
cant (p = 0.14). There was no association between
MUC1 expression levels and other variables including
age, histological types, SRC population, and SRC types.
The expression of MUC2, MUC4, MUC5AC and MUC6 in
association with clinicopathological variables
The expression patterns of MUC2, MUC4, MUC5AC
and MUC6, and their representative immunohistochemi-
cal findings are shown in Table 2 and Fig. 3 respectively.
MUC2 expression was detected in 2 MC cases, but not
in other cases. The expression of MUC4 and MUC5AC
was detected in 2 IDC cases, one of which showed both
MUC4 and MUC5AC expression. MUC6 expression was
identified in 10 patients, including 3 with IDC, 5 with
ILC, and 2 with MC. The expression levels of MUC2,
MUC4, MUC5AC, and MUC6 did not show a significant
correlation with any of the clinicopathological variables
including SRC population and SRC types.
Discussion
There have been some controversies concerning the def-
inition of SRCs and the SRC carcinoma of the breast in
the last decades. Previous reports indicated that SRCs
are originally derived from ILC; however, subsequent
studies found that SRCs can originate from other types
of breast cancers such as IDC and MC [9–13]. In ac-
cordance with these reports, our series of cases consisted
of a mixture of ILC, IDC, and MC cases, suggesting that
SRC can appear in any kind of breast carcinoma. The
2013 WHO classification classified SRCs as the ICL type
with targetoid appearance and the non-ICL type with
abundant intracytoplasmic mucin as observed in gastric
Fig. 2 Immunohistochemical expression of MUC1 (a–f). In normal breast tissue, MUC1 is constitutively expressed in the apical and luminal sites of
the ductal epithelia with weak cytoplasmic positivity (a). MUC1 was notably expressed in invasive ductal carcinoma (b and c) and invasive lobular
carcinoma (d and e) either in a luminal and cytoplasmic pattern (b and d) or in a cytoplasmic with membranous accentuation pattern (c and e).
All mucinous carcinoma cases showed the luminal and cytoplasmic pattern (f). Original magnification × 400 (a) and × 400 (b–f)
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carcinoma; however, the clinical significance of SRC
types remains uncertain [14]. In order to address this
issue, we compared cases with ICL and non-ICL types;
however, we did not observe significant differences in
clinicopathological parameters. Furthermore, the SRC
types did not correlate with any of the MUC protein ex-
pression tested. These findings indicate that classifying
SRC into two morphological types may have little or no
clinical significance.
A few earlier studies indicated that tumors with SRC
populations constituting more than 10–20 % of the tumor
cells are associated with poor prognosis [9, 29]. Neverthe-
less, the role of SRCs as an adverse prognostic factor for
breast cancer has not gained universal acceptance due to
the absence of sufficient evidence. In the present study,
we stratified the cases as SRC-high (>31 %) and SRC-low
(<30 %) groups, depending on the proportion of the SRC
population among the tumor cells, and found no signifi-
cant correlation with any of the clinicopathological vari-
ables. In fact, we have tested several thresholds including
40 % or 10 % to divide the cases; however, we were unable
to obtain any significant results (data not shown). Based
on these results, we suggest that the proportion of SRC
population within the breast tumor might not confer a
prognostic significance for breast cancer patients. How-
ever, these results should be interpreted with caution, con-
sidering the fact that our study was conducted using 22
cases with a relatively short follow-up period. Future stud-
ies with a large number of cases and a longer follow-up
periods are required to further elucidate the clinical sig-
nificance of SRCs.
MUC1 is normally present on the apical surface of the
secretory epithelium; however, its expression levels and
cellular localization are altered in malignant tumors [19].
The clinical significance of MUC1 expression in breast
cancer has been controversial due to the conflicting
results. Rakha et al. and others showed that the presence
of MUC1 at the apical cellular site of the ductal epithe-
lium is an indicator of intact MUC-pathway associated
with good prognosis, whereas aberrant patterns of expres-
sion are indicators of defective MUC1 pathway associated
with worse prognosis [17–19, 25]. By contrast, a few prior
studies concluded that MUC1 expression levels and/or
subcellular localization patterns are not of prognostic sig-
nificance [30, 31]. In the present study, we showed that
lower MUC1 expression levels and altered subcellular
localization patterns are associated with adverse clinico-
pathological variables. However, multivariate analysis did
not find a significant association between MUC1 expres-
sion pattern and an increase in recurrence rate. As our
study involves 22 patients, of whom only 2 had recur-
rence, the utility of MUC1 expression as a predictor of
clinical outcomes warrants a further study using a signifi-
cant number of cases.
MUC2 is a major secretory glycoprotein produced
mainly by the gastro-intestinal epithelial cells [32]. A pre-
vious study attributes the less aggressive behavior of MC
to the function of MUC2, which is frequently expressed in
Fig. 3 Immunohistochemical expression of MUC2 (a), MUC4 (b), MUC5AC (c) and MUC6 (d). Focal weak staining of MUC2 was observed in the
cytoplasm of mucinous carcinoma cells (a). Positive expression of MUC4 was observed in invasive ductal carcinoma cells including intracytoplasmic
mucin (b). Conspicuous expression of MUC5AC and MUC6 was noted in invasive ductal carcinoma (c) and mucinous carcinoma (d), but not in
intracytoplasmic mucin. Original magnification × 400 (a–d)
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MC [33]. Our findings are consistent with this study as in-
dicated by positive MUC2 expression in half of the MC
cases. The epithelial cells secrete MUC4 as a heterodimer
through a proteolytic cleavage mechanism, and the func-
tion of MUC4 is to protect vulnerable epithelia. Only a
few reports have thus far addressed the significance of
MUC4 in breast cancer. A study by Rahka et al. reported
MUC4 expression in 95 % of the breast cancer cases in
their series, and also detected a correlation with the nu-
clear grade [17]. In our series, we only observed MUC4
expression in 2 IDC cases, without any association to clin-
icopathological parameters. MUC5AC and MUC6 share
similar functions in protecting the mucosal membrane;
however, reports on their expressions in breast cancer are
limited. In our study, only one case showed significant ex-
pression of MUC5AC, consistent with a previous study
that showed MUC5AC expression in < 10 % of breast can-
cer cases [34]. Another previous study reported MUC6 ex-
pression in approximately 23 % of IDC cases examined,
and a separate study found association of higher expres-
sion of MUC6 with a good prognosis [17, 34]. On the
other hand, we detected significant MUC6 expression in
10 cases (45 %) including 3 IDC, 5 ILC and 2 MC cases.
The proportion of cases with MUC6 expression in our
series is similar to a recent report that shows MUC6 ex-
pression in 40 % of breast carcinoma cases; however, an
association between MUC6 expression and the clinico-
pathological variables was not identified [22].
Conclusion
In summary, our results indicate that instead of SRC
population and types, the expression level of MUC1
and/or the presence of cytoplasmic staining with circum-
ferential membranous accentuation pattern in breast
cancers showed significant association with adverse clini-
copathological parameters. The expression levels of
MUC2, MUC4, and MUC5AC had no clinical implica-
tion. The utility of MUC1 expression as a prognostic
indicator remains to be further assessed using a larger
number of cases.
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